Rapid eye movement sleep behaviour disorder – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 10:34:37 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Rapid eye movement sleep behaviour disorder – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study on the Effects and Safety of Piromelatine for Patients with Idiopathic Rapid Eye Movement Behavior Disorder (iRBD) https://clinicaltrials.eu/trial/study-on-the-effects-and-safety-of-piromelatine-for-patients-with-idiopathic-rapid-eye-movement-behavior-disorder-irbd/ Wed, 29 Apr 2026 14:57:24 +0000 https://clinicaltrials.eu/trial/study-on-the-effects-and-safety-of-piromelatine-for-patients-with-idiopathic-rapid-eye-movement-behavior-disorder-irbd/ This clinical trial is focused on studying a sleep disorder known as idiopathic Rapid Eye Movement Behavior Disorder (iRBD). This condition is characterized by unusual movements and vocal sounds during the rapid eye movement (REM) stage of sleep. The study will explore the effects of a medication called Piromelatine (Neu-P11), which is taken in tablet form. Piromelatine is a chemical compound that acts on certain receptors in the brain related to sleep regulation.

The purpose of the study is to assess the effectiveness and safety of Piromelatine over a short-term period of six weeks. Participants will take the medication and their sleep patterns will be monitored in a sleep laboratory setting. This involves observing changes in sleep behavior and any improvements in the symptoms of iRBD. The study will also monitor the participants’ overall health and any side effects that may occur during the treatment period.

Throughout the study, participants will undergo various assessments to evaluate the severity of their sleep disorder and the impact of the treatment. These assessments will include monitoring sleep stages, muscle activity, and other sleep-related variables. The study aims to provide valuable insights into how Piromelatine can help manage iRBD and improve the quality of sleep for those affected by this disorder.

]]>